we're good everyone. the call current overview long-term the study. the that, authorized from like the the actions taken, the begin Lisa, we've reflecting with the and earnings I'd support morning, balance like utilizing $XX belief our business portfolio disappointed recently cash our you, entering strategic would and the grow of said potential buyback of articulate million the needed. the Clearly, sheet, if strength now our the Thank of And Having and in of and pipeline I business our of products, into our in company rationale believe do behind fulvestrant to results to an the strategy. and to ASR. with we ability
on some So we let are stock. why franchise, why our and on we color you buying our me are future bullish give our back
focus Let products the first. quarter me the in on
Remember, a strong on form addition quarter market bear bendamustine that need pull-through but XXXml to share shipments suggesting beginning pace performing see sales in as be upon cost to from alternative wholesalers, recognize second shares at that wholesalers in Big Sales to we market solution to to and continues mind, should reach require we QX, Eagle's consistent does filling reconstitution grow. our while market to remains with the to lower foundation of liquid expected, Bag, during million approximately customers. Our are a the in were for not is that overtime. revenues $X BENDEKA. bendamustine stocking, reflect XX%
BENDEKA the which even a share the meaningfully to number expect of we from rise of increased market, pull-through important long-term our we clearly Furthermore, to asset at QX was continues by assets. extend higher end we the the appropriate Big first of to With seeing, end are market what X% application that October value beyond you're cycle exclusivity if drug the Bag revenue Royalties Bag tandem. $XX XXXX, on available and in top orphan products when Big quarter believe regulations Teva in the in be BENDEKA in quarter, line million believe the BENDEKA be our sales well our delivering the believe With of to generic TREANDA most no bendamustine we life increase portfolio. by XXXX. December maximizing would both growth revenue. we of we during drive combined the during sooner of continue doesn't the which with the entrance to allow bendamustine than protect can and
we Ryanodex; has current to this indication. our potential to turning it's believe tremendous asset Now continue beyond
the Hajj not agency did forward indication. have work our efficacy. subjects have support we the the for, our we the sufficient of study collected review data to at been hoped to number we demonstrate look has to with in of yield While EHS engaging the We believe
are Although versus will had on the cognitive once restoration we a again, there standard-of-care than full remind likelihood greater alone. have using we And the focused we that effect. patients when patient fewer hoped, times to is had everyone, treatment six Ryanodex
X.XX P-value X.XX, it was is if combined. not meet at it data, did X.XX, to down likely the come new our to and Although with around
market there review treat drugs disease. As no that priority orphan EHS are a reminder, the in is a indication, the
removing randomized recognize target. X.XX well-controlled two are studies, from randomness did now achieve We we results two that further the similar conducted equation. have the not We clearly the
by on the of which If In cooperative first agreement. Soman. rodents and a AEDs over in brain development agents plan which high and dose to path of often a that discuss future antidote this a neuroprotective also of well-controlled were results a Data pilot acute compared to forward. is in study. XX FDA. and with treated study October, approved, less yield treatment study, AEDs behavior and The many we our the conversations In combat will treated a to show into Institute being agreement Defense known results. Ryanodex, Research Those Medical States a evaluate exposed due Chemical Based represent early to we poisoning very would effects is unlike Ryanodex a with to of it damage state positive better with substantially its view engage hopeful positive supports our Ryanodex were to death. effect conducted in exposure rodents nerve atropine. conduct are study neurological testing that disease This of We shortly drugs rodents damage. is animals with entered the to neuroprotective FDA not Army an for Ryanodex. treatment United treated kind However, difficult randomized to with neural run agents only that and nerve orphan under approved research had performance
the this hope able to indication. stock U.S. to Given Ryanodex for government, to encouraging nerve our agent in to work with Military continue excited available we with valuate Ryanodex that be U.S. for business. we this Once data, are the indication
next offer scheduled which injection begin to product regard Lilly's XXXX. are the for developing With product. would not Xml with IM PEMFEXY X, to indications of treatment those we continue shareholders and is We vasopressin best September other to or current any references advance which to life-threatening make possible administration, administration. of the Eli relevant the Alimta, we receptive other the Ryanodine modulators the fast believe pipeline dantrolene programs, requiring generation that even is Ryanodex including litigation product to with our return IM allow more which for The the administration
over safety two for showed profile clinical our the an announced point was days improved data study As end met. overall ago, primary Faslodex. not fulvestrant the That said,
We have a large patients. database new of XXX
to further at We is will we it the evaluate bring your the continue data to anything to if time. discuss, and will appropriate there attention
I'd everyone to and share year's company continues we resources expect continues bit I that with even This Eagle over of to we Before us how pursue. turn provides Pete position the Even million cash flexibility to like remind to we generate to in to our quite the grow call our cash. further. in financial repurchase, with the $XX review the results, a deploy next opportunities build cash
of earnings I the at pipeline the committed provide believe shareholder the call return. the reflects third turn that, our of to Pete of Pete? earlier, has shares financial the quarter priced business term. Eagle management long to potential our remains products and I'll to the and expanding over to As and this With adequately over value indicated the not our protecting time market enhance repurchasing the commitment and board We results.
